The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Subscribe To Our Newsletter & Stay Updated
